Streptococcal toxic shock syndrome associated with necrotizing fasciitis

Annual Review of Medicine

Volumn 51, Issue , 2000, Pages 271-288

  Stevens, Dennis L ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Boise VA Medical Center   (United States)

Author keywords

Clindamycin; Cytokines; Myonecrosis; Septic shock; Streptococcus pyogenes; Superantigens

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CLINDAMYCIN; EXOTOXIN; GAMMA INTERFERON; IMMUNOGLOBULIN; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 6; LYMPHOTOXIN; SUPERANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

BLISTER; DEBRIDEMENT; DISEASE ASSOCIATION; EARLY DIAGNOSIS; FEVER; FLUID THERAPY; HUMAN; HYPOTENSION; MONOCYTE; NECROTIZING FASCIITIS; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS INFECTION; T LYMPHOCYTE; TOXIC SHOCK SYNDROME;

DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FASCIITIS, NECROTIZING; HUMANS; MYOSITIS; PUBLIC HEALTH; SHOCK, SEPTIC;

EID: 0034005888     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.51.1.271     Document Type: Review

References (81)

1. 1. Stanley J, Desai M, Xerry J, et al. 1996. High-resolution genotyping elucidates the epidemiology of group A streptococcus outbreaks. J. Infect. Dis. 174:500-6
2. 2. Kehoe MA, Kapur V, Whatmore AM, Musser JM. 1996. Horizontal gene transfer among A streptococci: implications for pathogenesis and epidemiology. Trends Microbiol. 4:436-43
3. 3. Weeks CR, Ferretti JJ. 1986. Nucleotide sequence of the type A streptococcal exotoxin (erythrogenic toxin) gene from Streptococcus pyogenes bacteriophage T12. Infect. Immun. 52:144-50
4. 4. Stevens DL. 1999. The flesh-eating bacterium: What's next? J. Infect. Dis. 179(Suppl. 2):S366-74
5. 5. Davies HD, McGeer A, Schwartz B, et al. 1996. Invasive group A streptococcal infections in Ontario, Canada. N. Engl. J. Med. 335:547-54
6. 6. Stevens DL. 1992. Invasive group A streptococcus infections. Clin. Infect. Dis. 14:2-11
7. 7. Stevens DL, Tanner MH, Winship J, et al. 1989. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N. Engl. J. Med. 321(1):1-7
8. 8. Holm SE, Norrby A, Bergholm AM, Norgren M. 1992. Aspects of pathogenesis of serious group A streptococcal infections in Sweden, 1988-1989. J. Infect. Dis. 166:31-37
9. 9. Wheeler MC, Roe MH, Kaplan EL, et al. 1991. Outbreak of group A streptococcus septicemia in children. Clinical, epidemiologic, and microbiological correlates. JAMA 266(4):533-37
10. 10. Thomas JC, Carr SJ, Fujioka K, Waterman SH. 1989. Community-acquired group A streptococcal deaths in Los Angeles county. J. Infect. Dis. 160(6): 1086-87
11. 11. Kohler W. 1990. Streptococcal toxic shock syndrome. Int. J. Med. Microbiol. Virol. Parasitol. Infect. Dis. 272:257-64
12. 12. Stevens DL. 1995. Streptococcal toxic shock syndrome: spectrum of disease, pathogenesis and new concepts in treatment. Emerg. Infect. Dis. 1:69-78
13. 13. Martin PR, Hoiby EA. 1990. Streptococcal serogroup A epidemic in Norway 1987-1988. Scand. J. Infect. Dis. 22: 421-29
14. 14. Chelsom J, Halstensen A, Haga T, Hoiby EA. 1994. Necrotising fasciitis due to group A streptococci in western Norway: incidence and clinical features. Lancet 344:1111-15
15. 15. Stevens DL. 1995. Streptococcal infections of skin and soft tissues. In Atlas of Infectious Diseases, ed. DL Stevens, GL Mandell, 11:3.1-3.11. Philadelphia: Churchill Livingstone
16. 16. Stamm WE, Feeley JC, Facklam RR. 1978. Wound infections due to group A streptococcus traced to a vaginal carrier. J. Infect. Dis. 138:287-92
17. 17. Bibler MR, Rouan GW. 1986. Cryptogenic group A Streptococcal bacteremia: experience at an urban general hospital and review of the literature. Rev. Infect. Dis. 8:941-51
18. 18. Adams EM, Gudmundsson S, Yocum DE, et al. 1985. Streptococcal myositis. Arch. Intern. Med. 145:1020-23
19. 19. Pfanner W. 1918. Zur Kenntnis und Behandlung des nekrotisierenden Erysipels. Dtsch. Z. Chir. 144:108
20. 20. Meleney FL. 1924. Hemolytic streptococcus gangrene. Arch. Surg. 9:317-64
21. 21. Svane S. 1971. Peracute spontaneous streptococcal myositis. A report on 2 fatal cases with review of literature. Acta Chir. Scand. 137:155-63
22. 22. Demers B, Simor AE, Vellend H, et al. 1993. Severe invasive group A Streptococcal infections in Ontario, Canada: 1987-1991. Clin. Infect. Dis. 16:792-800
23. 23. Nather A, Wong FY, Balasubramaniam P, Pang M. 1987. Streptococcal necrotizing myositis - a rare entity: a report of two cases. Clin. Orthop. 215:206-11
24. 24. Yoder EL, Mendez J, Khatib R. 1987. Spontaneous gangrenous myositis induced by Streptococcus pyogenes: case report and review of the literature. Rev. Infect. Dis. 9(2):382-85
25. 25. Bisno AL, Stevens DL. 1996. Streptococcal infections in skin and soft tissues. N. Engl. J. Med. 334:240-45
26. 26. Stevens DL, Musher DM, Watson DA, et al. 1990. Spontaneous, nontraumatic gangrene due to Clostridium septicum. Rev. Infect. Dis. 12(2):286-96
27. 27. Eagle H. 1952. Experimental approach to the problem of treatment failure with penicillin. I. Group A Streptococcal infection in mice. Am. J. Med. 13:389-99
28. 28. Stevens DL, Bryant-Gibbons AE, Bergstrom R, Winn V. 1988. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J. Infect. Dis. 158:23-28
29. 29. Lancefield RC. 1962. Current knowledge of type specific M antigens of group A streptococci. J. Immunol. 89:307-13
30. 30. Raeder RH, Woischnik M, Podbielski A, Boyle MD. 1998. A secreted streptococcal cysteine protease can cleave a surface-expressed M1 protein and alters the immunoglobulin binding properties. Res. Microbiol. 149:539-48
31. 31. Johnson DR, Stevens DL, Kaplan EL. 1992. Epidemiologic analysis of group A streptococcal serotypes associated with severe systemic infections, rheumatic fever, or uncomplicated pharyngitis. J. Infect. Dis. 166:374-82
32. 32. Kohler W, Gerlach D, Knoll H. 1987. Streptococcal outbreaks and erythrogenic toxin type A. Zentralbl. Bakteriol. Mikrobiol. Hyg. 266:104-15
33. 33. Fast DJ, Schlievert PM, Nelson RD. 1989. Toxic shock syndrome-associated staphylococcal and streptococcal pyrogenic toxins are potent inducers of tumor necrosis factor production. Infect. Immun. 57:291-94
34. 34. Hackett SP, Schlievert PM, Stevens DL. 1991. Cytokine production by human mononuclear cells in response to streptococcal exotoxins. Clin. Res. 39:189A (Abstr.)
35. 35. Norrby-Teglund A, Norgren M, Holm SE, et al. 1994. Similar cytokine induction profiles of a novel streptococcal exotoxin, MF, and pyrogenic exotoxins A and B. Infect. Immun. 62:3731-38
36. 36. Muller-Alouf H, Alouf JE, Gerlach D, et al. 1992. Cytokine production by murine cells activated by erythrogenic toxin type A superantigen of Streptococcus pyogenes. Immunobiology 186:435-48
37. 37. Hallas G. 1985. The production of pyrogenic exotoxins by group A streptococci. J. Hyg. 95:47-57
38. 38. Mollick JA, Miller GG, Musser JM, et al. 1993. A novel superantigen isolated from pathogenic strains of Streptococcus pyogenes with ammoterminal homology to staphylococcal enterotoxins B and C. J. Clin. Invest. 92:710-19
39. 39. Norrby-Teglund A, Newton D, Kotb M, et al. 1994. Superantigenic properties of the group A streptococcal exotoxin SpeF (MF). Infect. Immun. 62:5227-33
40. 40. Mollick JA, Rich RR. 1991. Characterization of a superantigen from a pathogenic strain of Streptococcus pyogenes. Clin. Res. 39(2):213 (Abstr.)
41. 41. Hackett SP, Stevens DL. 1992. Streptococcal toxic shock syndrome: synthesis of tumor necrosis factor and interleukin-1 by monocytes stimulated with pyrogenic exotoxin A and streptolysin O. J. Infect. Dis. 165:879-85
42. 42. Kotb M, Tomai M, Majumdar G, et al. 1990. Cellular and biochemical responses of human T lymphocytes stimulated with streptococcal M protein. Lancefield Int. Symp. Streptococcal Dis., XI, Sienna, Italy #L77 (Abstr.)
43. 43. Watanabe-Ohnishi R, Low DE, McGeer A, et al. 1995. Selective depletion of V beta-bearing T cells in patients with severe invasive group A streptococcal infections and streptococcal toxic shock syndrome, Ontario Streptococcal Study Project. J. Infect. Dis. 171:74-84
44. 44. Stevens DL, Bryant AE, Hackett SP. 1992. Gram-positive shock. Curr. Opin. Infect. Dis. 5(3):355-63
45. 45. Hackett S, Ferretti J, Stevens D. 1994. Cytokine induction by viable group A streptococci: suppression by streptolysin O. Prog. Abstr. Am. Soc. Microbiol, Las Vegas, NV, B-249:73 (Abstr.). Washington, DC: Am. Soc. Microbiol.
46. 46. Muller-Alouf H, Alouf JE, Gerlach D, et al. 1994. Comparative study of cytokine release by human peripheral blood mononuclear cells stimulated with Streptococcus pyogenes superantigenic erythrogenic toxins, heat-killed streptococci, and lipopolysaccharide. Infect. Immun. 62:4915-21
47. 47. Hackett SP, Stevens DL. 1993. Superantigens associated with staphylococcal and streptococcal toxic shock syndromes are potent inducers of tumor necrosis factor beta synthesis. J. Infect. Dis. 168(1):232-35
48. 48. Kappur V, Majesky MW, Li LL, et al. 1993. Cleavage of interleukin 1β (IL-1β) precursor to produce active IL-1β by a conserved extracellular cysteine protease from Streptococcus pyogenes. Proc. Natl. Acad. Sci. USA 90:7676-80
49. 49. Chaussee MS, Liu J, Stevens DL, Ferretti JJ. 1996. Genetic and phenotypic diversity among isolates of Streptococcus pyogenes from invasive infections. J. Infect. Dis. 173:901-8
50. 50. Burns EH, Marciel AM, Musser JM. 1996. Activation of a 66-kilodalton human endothelial cell matrix metalloprotease by Streptococcus pyogenes extracellular cysteine protease. Infect. Immun. 64:4744-50
51. 51. Cleary P, Chen C, Lapenta D, et al. 1990. A virulence regulon in Streptococcus pyogenes. Prog. Abstr. Int. Am. Soc. Microbiol. Conf. Streptococcal Genet., 3rd, Minneapolis, MN, 19:12 (Abstr.) Washington, DC: Am. Soc. Microbiol.
52. 52. Cleary PP, Kaplan EL, Handley JP, et al. 1992. Clonal basis for resurgence of serious Streptococcus pyogenes disease in the 1980s. Lancer 339:518-21
53. 53. Musser JM, Hauser AR, Kim MH, et al. 1991. Streptococcus pyogenes causing toxic-shock-like syndrome and other invasive diseases: clonal diversity and pyrogenic exotoxin expression. Proc. Natl. Acad. Sci. USA 88:2668-72
54. 54. Kim KS, Kaplan EL. 1985. Association of penicillin tolerance with failure to eradicate group A streptococci from patients with pharyngitis. J. Pediatr. 107:681-84
55. 55. Gatanaduy AS, Kaplan EL, Huwe BB, et al. 1980. Failure of penicillin to eradicate group A streptococci during an outbreak of pharyngitis. Lancet 2:498-502
56. 56. Brook I. 1985. Role of beta-lactamase-producing bacteria in the failure of penicillin to eradicate group A streptococci. Pediatr. Infect Dis. 4:491-95
57. 57. Hribalova V. 1988. Streptococcus pyogenes and the toxic shock syndrome. Ann. Intern. Med. 108:772
58. 58. Gaworzewska ET, Coleman G. 1989. Group A streptococcal infections and a toxic shock-like syndrome [letter]. N. Engl. J. Med. 321(22): 1546
59. 59. Stevens DL, Bryant AE, Yan S. 1994. Invasive group A Streptococcal infection: new concepts in antibiotic treatment. Int. J. Antimicrob. Agents 4:297-301
60. 60. Stevens DL, Yan S, Bryant AE. 1993. Penicillin binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect. J. Infect. Dis. 167:1401-5
61. 61. Yan S, Mendelman PM, Stevens DL. 1993. The in vitro antibacterial activity of ceftriaxone against Streptococcus pyogenes is unrelated to penicillin-binding protein 4. FEMS Microbiol. Lett. 110:313-18
62. 62. Van S, Bohach GA, Stevens DL. 1994. Persistent acylation of high-molecular-weight penicillin binding proteins by penicillin induces the postantibiotic effect in Streptococcus pyogenes. J. Infect. Dis. 170:609-14
63. 63. Stevens DL, Maier KA, Mitten JE. 1987. Effect of antibiotics on toxin production and viability of Clostridium perfringens. Antimicrob. Agents Chemother. 31:213-18
64. 64. Gemmell CG, Peterson PK, Schmeling D, et al. 1981. Potentiation of opsonization and phagocytosis of Streptococcus pyogenes following growth in the presence of clindamycin. J. Clin. Invest. 67:1249-56
65. 65. Stevens DL, Bryant AE, Hackett SP. 1995. Antibiotic effects on bacterial viability, toxin production, and host response. Clin. Infect. Dis. 20(Suppl. 2):S154-57
66. 66. Barry W, Hudgins L, Donta S, Pesanti E. 1992. Intravenous immunoglobulin therapy for toxic shock syndrome. JAMA 267:3315-16
67. 67. Yong JM. 1994. Necrotising fasciitis [letter]. Lancet 343:1427
68. 68. Kaul R, McGeer A, Norrby-Teglund A, et al. 1999. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome - a comparative observational study. Clin. Infect. Dis. 28:800-7
69. 69. Stevens DL, Bryant AE, Hackett SP, et al. 1996. Group A streptococcal bacteremia: the role of tumor necrosis factor in shock and organ failure. J. Infect. Dis. 173:619-26
70. 70. Cockerill FR, MacDonald KL, Thompson RL, et al. 1997. An outbreak of invasive group A streptococcal disease associated with high carriage rates of the invasive clone among school-aged children. JAMA 277(1):38-43
71. 71. Hohenboken JJ, Anderson F, Kaplan EL. 1994. Invasive group A streptococcal (GAS) serotype M-1 outbreak in a long-term care facility (LTCF) with mortality. Prog. Abstr. Intersci. Conf. Antimicrob. Agents Chemother., Orlando, FL, J189:192 (Abstr.). Washington, DC: Am. Soc. Microbiol.
72. 72. Auerbach SB, Schwartz B, Williams D, et al. 1992. Outbreak of invasive group A streptococcal infections in a nursing home. Lessons on prevention and control. Arch. Intern. Med. 152(5):1017-22
73. 73. Schwartz B, Elliot JA, Butler JC, et al. 1992. Clusters of invasive group A streptococcal infections in family, hospital, and nursing home settings. Clin. Infect. Dis. 15(2):277-84
74. 74. Valenzuela TD, Hooton TM, Kaplan EL, Schlievert PM . 1991. Transmission of "toxic strep" syndrome from an infected child to a firefighter during CPR. Ann. Emerg. Med. 20:1:123-25
75. 75. Dipersio JR, File TM, Stevens DL, et al. 1996. Spread of serious disease-producing M3 clones of group A streptococcus among family members and health care workers. Clin. Infect. Dis. 22:490-95
76. 76. Stegmayr B, Bjorck S, Holm S, et al. 1992. Septic shock induced by group A streptococcal infections: clinical and therapeutic aspects. Scand. J. Infect. Dis. 24:589-97
77. 77. Stevens DL. 1995. Could nonsteroidal anti-inflammatory drugs (NSAIDs) enhance the progression of bacterial infections to toxic shock syndrome? Clin. Infect. Dis. 21:977-80
78. 78. Greenberg LJ, Gray ED, Yunis E. 1975. Association of HL-A5 and immune responsiveness in vitro to streptococcal antigens. J. Exp. Med. 141:934-43
79. 79. Weinstein L, Barza M. 1972. Gas gangrene. N. Engl. J. Med. 289:1129-31
80. 80. Zabriskie JB, Lavenchy D, Williams RC Jr, et al. 1985. Rheumatic-fever associated B-cell alloantigens as identified by monoclonal antibodies. Arthritis Rheum. 28:1047-51
81. 81. Stevens DL. 1992. Streptococcal toxic shock syndrome. Infect. Med. 9(7):33-39